AI Medical Advice Is Moving Faster Than Healthcare Risk Management
As patients increasingly rely on AI tools for health-related questions, healthcare organizations need to understand how those tools are being used, who is relying on them, and where legal, clinical, and operational risk may begin.
Artificial intelligence is quickly becoming part of the healthcare experience. Patients are using AI tools to ask questions, interpret symptoms, manage medications, and decide whether they need to seek care. Some of these tools are being introduced through formal healthcare partnerships. Others are consumer-facing platforms that were never designed to operate as part of the healthcare system.
The problem is that patients are not always seeing the difference between a tool that gives general information and a tool that sounds like it is giving medical guidance. This is where real risks comes in.
The recent lawsuit in Pennsylvania involving Character.AI is a reminder that healthcare risk is no longer limited to hospitals, physicians, pharmacies, or traditional medical technology companies. When patients rely on AI-generated information to make decisions about their health, the legal and regulatory questions become much more complicated.
Who is responsible if the information is wrong? Was the platform providing general information, or did it cross into something closer to medical advice? Did the user understand the limits of the tool? Was there any process for escalation, disclosure, clinical review, or human oversight?
These questions matter because AI is not entering healthcare through one clean channel. It is coming through consumer applications, state partnerships, provider workflows, payer systems, pharmacy tools, and patient-facing platforms. Some uses may be administrative. Others may influence clinical decision-making in ways that are not obvious at the beginning.
That creates a different kind of risk environment for healthcare organizations.
The issue is not whether AI should be used in healthcare. It will be used and increasingly so. The more important question is whether healthcare organizations have the governance structure to understand how it is being used, who is relying on it, and where the legal risk sits.
For providers, pharmacies, health systems, digital health companies, and other healthcare organizations, AI review cannot sit only with the technology team. It needs to involve legal, compliance, clinical, operational, and risk management leadership before the tool is placed in front of patients or built into a workflow.
That review should start with practical questions. What is the tool actually doing? Is it generating general information, making recommendations, triaging care, renewing medications, or influencing a provider’s decision? Who reviews the output? What disclosures are being made to patients? How are errors identified? What happens when the AI reaches the limit of what it should answer?
The answers to those questions may determine whether an organization is using AI as a helpful support tool or unintentionally creating a new source of professional, regulatory, and operational exposure.
Healthcare has always depended on trust. AI does not remove that obligation. It simply changes where the trust is being placed.
As AI becomes more visible in healthcare, the organizations that move carefully will not be the ones avoiding innovation. They will be the ones that understand that innovation needs structure around it.